अApnaFunda
Menu

KRSNAA DIAGNOSTICS LIMITED (KRSNAA)

Health Services · Medical/Nursing Services · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.46 / 100
Profitability 50Growth 57Balance sheet 29
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.54 / 100
Price 30Earnings 51FII/DII 81

Passes these screensValue Pick

Compare withDR. LAL PATHLABSVIJAYA DIAGNOSTIC CENTREMETROPOLIS HEALTHCARE

Share price

Closing priceAdjusted for splits and bonus issues.

₹493.6 latest close · −12.3% over the last 90 sessions

₹500₹550Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹500₹550Jul 3Sep 4Nov 9

₹493.6 month-end · −39.1% over 12 months

₹500₹600₹700₹800Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹500₹600₹700₹800Nov '25May '26Nov '26

₹493.6 month-end · −23.5% over 3 years

₹600₹800₹1,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹600₹800₹1,000Nov '23May '25Nov '26

₹493.6 month-end · −48.2% since Aug '21

₹400₹600₹800₹1,000Aug '21Sep '22Sep '23Oct '24Oct '25Nov '26 ₹400₹600₹800₹1,000Aug '21Apr '24Nov '26

52-week range ₹463.10 to ₹838.00 · 1-year volatility 29.7%

Was the rally earned?

-39%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

  • Per-share earnings added 15 points, but investors now pay less per rupee of profit (P/E 32.7x to 16.4x), which took 54 points back.
  • The share count barely moved.
Net profit growth: +15 pts. Points of the price return explained by net profit growing (or shrinking).+15 ptsNet profit growthP/E change: −54 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−54 ptsP/E changeShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1 ptsShare count changeShare price: −39%−39%Share priceNet profit growth: +15 pts. Points of the price return explained by net profit growing (or shrinking).+15ProfitP/E change: −54 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−54P/EShare count change: +1 pts. Points of the price return explained by the share count changing. More shares count against the price.+1SharesShare price: −39%−39%Share price
Net profit growth+15 ptsNet profit rose about 20%, which lifts the price.
P/E change-54 ptsThe P/E fell from 32.7x to 16.4x, which lowers the price.
Share count change+1 ptsShare count was little changed. More shares would count against the price.
-24%share price, 3 yearsLower P/E held it back

Earnings helped, the multiple did not.

  • Per-share earnings added 37 points, but investors now pay less per rupee of profit (P/E 32.6x to 16.4x), which took 60 points back.
  • The share count rose 3%.
Net profit growth: +40 pts. Points of the price return explained by net profit growing (or shrinking).+40 ptsNet profit growthP/E change: −60 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−60 ptsP/E changeShare count change: −3 pts. Points of the price return explained by the share count changing. More shares count against the price.−3 ptsShare count changeShare price: −23%−23%Share priceNet profit growth: +40 pts. Points of the price return explained by net profit growing (or shrinking).+40ProfitP/E change: −60 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−60P/EShare count change: −3 pts. Points of the price return explained by the share count changing. More shares count against the price.−3SharesShare price: −23%−23%Share price
Net profit growth+40 ptsNet profit rose about 57%, which lifts the price.
P/E change-60 ptsThe P/E fell from 32.6x to 16.4x, which lowers the price.
Share count change-3 ptsShare count rose 3%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with DR. LAL PATHLABS

How rough has the ride been?

Maximum drawdown-63.5%recovered 2024-11
1-year volatility29.7%annualised
Beta vs sector index0.623-year daily, correlation 0.31
Volume spikes4last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%−60%20222023202420252026−63.3% 0%−20%−40%−60%202220242026−63.3%
Largest drawdowns

-63.5% (2021-08 peak to 2023-03 low, recovered 2024-11)

-53.4% (2024-11 peak to 2026-11 low, not yet recovered)

Most recent volume spikes

2026-11-03: 6.5x the 50-day median, price -2.6% that day

2026-11-02: 7.8x the 50-day median, price -1.0% that day

2026-09-17: 68.3x the 50-day median, price +0.9% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

16.4xP/E todayNear its historic low
Against its own history2nd percentile
CheapestMedian 29.0xDearest

Usual range 18.0x to 39.0x since 2021-08.

Against Health Services16.4x vs 50.9x
This company
16.4x
Sector median
50.9x

68% below the Health Services median.

16.4x34.5x52.5x70.6xAug '21Sep '22Oct '23Nov '24Dec '25Nov '2616.4x34.5x52.5x70.6xAug '21May '23Feb '25Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Services median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Services is valued

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE35th▼ 4 pts vs a year ago
  • Op. margin66th▼ 11 pts vs a year ago
  • Revenue growth12th▼ 34 pts vs a year ago
  • EPS growth66th▼ 6 pts vs a year ago
  • Debt/equity ↓27th▼ 34 pts vs a year ago
  • Cash cycle ↓13thflat vs a year ago
  • P/E ↓95th▲ 5 pts vs a year ago
  • 12M momentum20th▲ 3 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What is the price implying?

~16%annual earnings growth implied by the price

At a P/E of 22.0x, the price would imply about 15.7%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Services The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹493.60
P/E
16.4x
ROCE
13.0%
Market Cap
₹1600 cr
Revenue (TTM)
₹816 cr
P/S
2.0x
P/B
1.6x
ROE
9.9%
Operating Margin
25.0%
Debt / Equity
0.5x
Promoter Holding
27.1%
12M Momentum
-39.1%

52-week range

₹463.10₹838.00
8% of the way from its 52-week low to its high

Price risk

1Y volatility
29.7%
Beta vs sector
1-year daily
0.43

Balance sheet & cash

Interest cover
operating profit ÷ interest
3.9x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.08x
Share count, 1Y
unchanged

Are profits backed by cash?

3 of 6checks within range2 beyond a threshold
Other income reliance37%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 37.3%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate24%Within range

Median quarterly effective tax rate over about 2.5 years: 23.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.08xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.08x (cash from operations ₹254 cr, net profit ₹236 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow0 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 0. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+36 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 36 days (140 vs 104). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress32% of fixed assetsWithin range

Capital work-in-progress is 32% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs trimmed 4.2 pts; promoters trimmed 0.7 pts; FIIs added 0.6 pts.
  • The number of shareholders fell from 60,665 to 53,625 (-12%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters27.8%27.1%-0.7 pts
FIIs3.7%4.3%+0.6 pts
DIIs18.7%14.5%-4.2 pts
Public and others49.8%54.1%+4.3 pts

Number of shareholders

53,625shareholders-12% since Sep '23
52k55k58k61k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 60,665
Dec '23: 57,232
Mar '24: 56,458
Jun '24: 55,914
Sep '24: 53,519
Dec '24: 52,799
Mar '25: 53,559
Jun '25: 54,262
Sep '25: 52,117
Dec '25: 52,380
Mar '26: 53,022
Jun '26: 53,625
 52k55k58k61k Sep '23Sep '24Sep '25Jun '26
Sep '23: 60,665
Dec '23: 57,232
Mar '24: 56,458
Jun '24: 55,914
Sep '24: 53,519
Dec '24: 52,799
Mar '25: 53,559
Jun '25: 54,262
Sep '25: 52,117
Dec '25: 52,380
Mar '26: 53,022
Jun '26: 53,625

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+8.8%typical 12-month return vs the marketAbove the base rate
  • We found 50 past situations where a non-financial company looked like KRSNAA DIAGNOSTICS LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −5% to +43% vs the market, against −1% for all non-financial companies in the same months.
  • The analogs' median sat above that base rate (gap +9.6%, 80% range +3.7% to +23.5%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
ASIANTILES · Mar 2022: −50.2% vs market
SDBL · Apr 2020: −47.7% vs market
AWHCL · Oct 2025: −46.3% vs market
SULA · Aug 2025: −45.2% vs market
GLENMARK · Aug 2021: −34.7% vs market
GATEWAY · Dec 2024: −29.3% vs market
GRINFRA · Jan 2023: −29.3% vs market
CEATLTD · May 2021: −29.0% vs market
SPECIALITY · Aug 2024: −27.3% vs market
5PAISA · Jan 2025: −20.4% vs market
EVEREADY · Jun 2024: −11.7% vs market
APEX · Jun 2021: −11.0% vs market
SOMANYCERA · Jan 2023: −5.9% vs market
SHK · Oct 2022: −4.0% vs market
JKIL · Nov 2020: −2.4% vs market
INDOCO · Jul 2024: +1.5% vs market
TIRUMALCHM · Jun 2023: +2.4% vs market
EPL · Apr 2024: +2.5% vs market
NILKAMAL · Apr 2022: +2.9% vs market
MATRIMONY · Feb 2024: +4.0% vs market
RAJRATAN · Feb 2025: +4.4% vs market
SUDARSCHEM · Oct 2022: +5.1% vs market
BIRLACORPN · May 2022: +5.4% vs market
TVSSRICHAK · Apr 2020: +6.1% vs market
KNRCON · Oct 2022: +8.0% vs market
LUXIND · Aug 2023: +9.5% vs market
EXXARO · Sep 2022: +10.3% vs market
NRBBEARING · Feb 2022: +19.5% vs market
GREENPLY · Apr 2023: +20.2% vs market
AARTIDRUGS · Jul 2022: +23.7% vs market
BANARISUG · Jul 2021: +26.6% vs market
CARYSIL · Nov 2024: +27.9% vs market
RAMCOCEM · Nov 2022: +28.8% vs market
MMFL · Jan 2022: +32.9% vs market
FSL · Jan 2023: +36.2% vs market
STERTOOLS · Nov 2021: +37.9% vs market
VRLLOG · Sep 2020: +41.1% vs market
SATIA · Dec 2021: +43.2% vs market
SANSERA · Nov 2023: +46.2% vs market
HFCL · Nov 2023: +49.8% vs market
TCI · Jun 2020: +50.9% vs market
DOLLAR · Aug 2020: +52.1% vs market
KCP · May 2020: +54.0% vs market
GREENLAM · Dec 2020: +69.7% vs market
JKLAKSHMI · Aug 2020: +70.1% vs market
LIBERTSHOE · Oct 2021: +73.2% vs market
GANECOS · Dec 2023: +74.9% vs market
PURVA · Oct 2020: +83.4% vs market
MAHSEAMLES · Jun 2021: +112.2% vs market
BECTORFOOD · Jun 2022: +148.9% vs market
Similar setups +8.8%All companies −0.8%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median
+8.8%
All companies' median
−0.8%
Beat the market
70% vs 49%

50 past situations · 50 companies · 42 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
BANARISUG
Process Industries		 Jul 2021 25x7% +41%−13% +27%
SULA
Process Industries		 Aug 2025 30x13% −50%−50% −45%
INDOCO
Health Technology		 Jul 2024 31x10% +5%−19% +2%
EPL
Process Industries		 Apr 2024 26x12% +4%−21% +3%
GATEWAY
Non-Energy Minerals		 Dec 2024 17x13% −23%−33% −29%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
NRBBEARING
Producer Manufacturing		 Feb 2022 21x11% +2%−35% +20%
SOMANYCERA
Producer Manufacturing		 Jan 2023 26x12% −39%−39% −6%
AWHCL
Transportation		 Oct 2025 18x12% −33%−35% −46%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and ROCE. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to KRSNAA DIAGNOSTICS LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

GATEWAY DISTRIPARKSGATEWAY
Non-Energy Minerals
63%similar
promoter holdingvolatility
CARYSILCARYSIL
Consumer Durables
54%similar
revenue growthrevenue
SAMHI HOTELSSAMHI
Consumer Services
52%similar
revenue growthoperating margin
ARVIND SMARTSPACESARVSMART
Finance
51%similar
revenueROCE
STYRENIX PERFOM. MATERIALSSTYRENIX
Process Industries
49%similar
revenue growthROCE
JUPITER LIFE LINE HOSP.JLHL
Health Services
42%similar
revenue growthvolatility
RAINBOW CHILDRENS MEDICARERAINBOW
Health Services
41%similar
debt/equityoperating margin
ARTEMIS MEDICARE SERVICESARTEMISMED
Health Services
38%similar
revenueROCE

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Mar '23

  1. NovPriceFell 53% from the Nov 2024 peak to the Nov 2026 low.
  2. NovPriceVolume reached 7.8x its 50-day median on 2026-11-02; price -1.0% that day.
  3. SepPriceVolume reached 68.3x its 50-day median on 2026-09-17; price +0.9% that day.
  4. JulPeer rankMoved into the 2nd quartile of Health Services on EPS growth (from the 3rd quartile).
  5. MayPriceVolume reached 10.2x its 50-day median on 2026-05-26; price -0.9% that day.
  6. MarValuationP/E fell below the 10th percentile of its own history to date (21.0x).
  7. MarPeer rankSlipped to the 3rd quartile of Health Services on EPS growth (from the 2nd quartile).
  8. FebPeer rankSlipped to the 2nd quartile of Health Services on operating margin (from the top quartile).
Show 22 earlier events
  1. NovPriceVolume reached 51.8x its 50-day median on 2025-11-10; price +7.6% that day.
  2. SepPeer rankSlipped to the 2nd quartile of Health Services on EPS growth (from the top quartile).
  3. JulPriceVolume reached 9.7x its 50-day median on 2025-07-08; price +5.3% that day.
  4. JunPeer rankMoved into the top quartile of Health Services on EPS growth (from the 3rd quartile).
  5. MayPriceVolume reached 10.1x its 50-day median on 2025-05-13; price -7.6% that day.
  6. JanPriceVolume reached 6.4x its 50-day median on 2025-01-06; price +0.7% that day.
  7. DecResultsYear-on-year EPS growth turned positive.
  8. DecPeer rankMoved into the top quartile of Health Services on operating margin (from the 2nd quartile).
  9. NovPriceRegained the 2021-08 peak, 20 months after the low.
  10. OctPriceVolume reached 7.4x its 50-day median on 2024-10-30; price +6.8% that day.
  11. SepPeer rankSlipped to the 2nd quartile of Health Services on operating margin (from the top quartile).
  12. JulValuationP/E crossed above the 90th percentile of its own history to date (38.1x).
  13. JulPriceVolume reached 16.3x its 50-day median on 2024-07-03; price +7.4% that day.
  14. JunResultsRevenue (TTM) reached a new high of ₹619 cr.
  15. JunInstitutionsFII + DII holding fell 3.7 pts over 2 quarters to 18.7%.
  16. JunPriceVolume reached 10.1x its 50-day median on 2024-06-12; price +6.5% that day.
  17. DecPriceVolume reached 5.1x its 50-day median on 2023-12-19; price +4.8% that day.
  18. JulPriceVolume reached 22.4x its 50-day median on 2023-07-20; price -14.3% that day.
  19. JunResultsRevenue (TTM) reached a new high of ₹487 cr.
  20. JunPeer rankSlipped to the 3rd quartile of Health Services on ROCE (from the 2nd quartile).
  21. MayPriceVolume reached 12.2x its 50-day median on 2023-05-09; price -0.4% that day.
  22. MarPriceFell 64% from the Aug 2021 peak to the Mar 2023 low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history64 months · 2021-08 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1116.4x₹816 cr9.9%13.0%0.5x
2026-1016.8x₹816 cr10.0%13.0%0.5x
2026-0918.6x₹816 cr10.0%13.0%0.5x
2026-0817.7x₹773 cr10.4%13.0%0.5x
2026-0716.9x₹773 cr10.4%13.0%0.5x
2026-0617.4x₹773 cr10.4%13.0%0.5x
2026-0522.1x₹766 cr9.2%12.0%0.2x
2026-0423.7x₹766 cr9.2%12.0%0.2x
2026-0321.0x₹766 cr9.2%12.0%0.2x
2026-0224.3x₹760 cr9.6%12.0%0.2x
2026-0127.3x₹760 cr9.6%12.0%0.2x
2025-1227.6x₹760 cr9.6%12.0%0.2x
2025-1132.7x₹740 cr9.2%12.0%0.2x
2025-1031.3x₹740 cr9.2%12.0%0.2x
2025-0930.5x₹740 cr9.2%12.0%0.2x
2025-0832.8x₹717 cr8.8%12.0%0.2x
2025-0735.8x₹717 cr8.8%12.0%0.2x
2025-0629.3x₹717 cr8.8%12.0%0.2x
2025-0527.3x₹697 cr9.4%10.0%0.2x
2025-0431.2x₹697 cr9.4%10.0%0.2x
2025-0333.6x₹697 cr9.4%10.0%0.2x
2025-0233.1x₹680 cr8.6%10.0%0.2x
2025-0139.4x₹680 cr8.6%10.0%0.2x
2024-1241.3x₹680 cr8.6%10.0%0.2x
2024-1153.2x₹649 cr7.4%10.0%0.2x
2024-1050.3x₹649 cr7.4%10.0%0.2x
2024-0945.0x₹649 cr7.4%10.0%0.2x
2024-0840.5x₹619 cr7.0%10.0%0.2x
2024-0738.1x₹619 cr7.0%10.0%0.2x
2024-0634.1x₹619 cr7.0%10.0%0.2x
2024-0528.9x₹487 cr8.4%12.0%0.0x
2024-0429.1x₹487 cr8.4%12.0%0.0x
2024-0331.1x₹487 cr8.4%12.0%0.0x
2024-0233.0x₹487 cr8.4%12.0%0.0x
2024-0135.2x₹487 cr8.4%12.0%0.0x
2023-1235.7x₹487 cr8.4%12.0%0.0x
2023-1132.6x₹487 cr8.4%12.0%0.0x
2023-1035.4x₹487 cr8.4%12.0%0.0x
2023-0934.4x₹487 cr8.4%12.0%0.0x
2023-0831.6x₹487 cr8.4%12.0%0.0x
2023-0726.2x₹487 cr8.4%12.0%0.0x
2023-0629.6x₹487 cr8.4%12.0%0.0x
2023-0526.9x₹455 cr9.9%—0.1x
2023-0423.2x₹455 cr9.9%—0.1x
2023-0321.1x₹455 cr9.9%—0.1x
2023-0216.6x₹455 cr9.9%—0.1x
2023-0119.5x₹455 cr9.9%—0.1x
2022-1221.2x₹455 cr9.9%—0.1x
2022-1122.0x₹455 cr9.9%—0.1x
2022-1021.7x₹455 cr9.9%—0.1x
2022-0922.9x₹455 cr9.9%—0.1x
2022-0822.1x₹455 cr9.9%—0.1x
2022-0725.4x₹455 cr9.9%—0.1x
2022-0624.6x₹455 cr9.9%—0.1x
2022-05—₹61 cr-0.6%7.0%9.3x
2022-04—₹61 cr-0.6%7.0%9.3x
2022-03—₹61 cr-0.6%7.0%9.3x
2022-02—₹61 cr-0.6%7.0%9.3x
2022-01—₹61 cr-0.6%7.0%9.3x
2021-12—₹61 cr-0.6%7.0%9.3x
2021-11—₹61 cr-0.6%7.0%9.3x
2021-10—₹61 cr-0.6%7.0%9.3x
2021-09—₹61 cr-0.6%7.0%9.3x
2021-08—₹61 cr-0.6%7.0%9.3x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback